Kanser Tedavisinde Güncel ve Gelecek Yaklaşımlar

WHO, 2025 Erişim Tarihi: 06.12.2025

URL: https://www.who.int/news-room/fact-sheets/detail/cancer

Wiernik, A., Rogado, A., O'Mahony, D., & Abdul Razak, A. R. (2024). Elevating Cancer Care Standards Worldwide: An Analysis of Global Initiatives and Progress. JCO global oncology, 10, e2400199. https://doi.org/10.1200/GO.24.00199

Katta, B., Vijayakumar, C., Dutta, S., Dubashi, B., & Nelamangala Ramakrishnaiah, V. P. (2023). The Incidence and Severity of Patient-Reported Side Effects of Chemotherapy in Routine Clinical Care: A Prospective Observational Study. Cureus, 15(4), e38301. https://doi.org/10.7759/cureus.38301

Yao, L., Jiang, B., & Xu, D. (2025). Strategies to combat cancer drug resistance: focus on copper metabolism and cuproptosis. Cancer drug resistance (Alhambra, Calif.), 8, 15. https://doi.org/10.20517/cdr.2025.41 3.

Gulati G. (2022). Cardioprotection in breast cancer patients: one size fits all?. European heart journal, 43(27), 2570–2572. https://doi.org/10.1093/eurheartj/ehab810

Dabas, P., & Danda, A. (2023). Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy. Medical oncology (Northwood, London, England), 40(9), 275. https://doi.org/10.1007/s12032-023-02146-y

Meisel, J. L., Venur, V. A., Gnant, M. & Carey, L. Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet. 38, 78–86 (2018)

Arya, M., Shergill, I. S., Grange, P. & Emberton, M. Hormone therapy: a revolution in understanding prostate cancer. Lancet Oncol. 9, 1112 (2008).

Schechter, A. L. et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312, 513–516 (1984). 37.

Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).

Enewold, L. & Thomas, A. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for NonSmall Cell Lung Cancer in the United States. PLOS ONE 11, e0156728 (2016).

Horak, P. et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet. Med. Off. J. Am. Coll. Med. Genet. 24, 986–998 (2022).

Li, M. M. et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. JMD 19, 4–23 (2017).

Senapati, J. et al. Management of chronic myeloid leukemia in 2023 – common ground and common sense. Blood Cancer J. 13, 58 (2023).

Sonkin, D. & Simon, R. Early Detection is as Important as Imatinib in CML Treatment Success. http://www.preprints.org/manuscript/201910.0207/v1 (2019) doi:10.20944/preprints201910.0207.v1.

Correia, J. H., Rodrigues, J. A., Pimenta, S., Dong, T. & Yang, Z. Photodynamic Therapy Review: Principles, Photosensitizers, Applications, and Future Directions. Pharmaceutics 13, 1332 (2021).

Shastry, M. et al. Rise of Antibody-Drug Conjugates: The Present and Future. Am. Soc. Clin. Oncol. Educ. Book e390094 (2023) doi:10.1200/EDBK_390094.

Bagchi, S., Yuan, R. & Engleman, E. G. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu. Rev. Pathol. Mech. Dis. 16, 223–249 (2021).

Tawbi, H. A. et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N. Engl. J. Med. 386, 24–34 (2022).

Johnson, D. B., Nebhan, C. A., Moslehi, J. J. & Balko, J. M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat. Rev. Clin. Oncol. 19, 254–267 (2022).

Tian, Z., Liu, M., Zhang, Y. & Wang, X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J. Hematol. Oncol.J Hematol Oncol 14, 75 (2021).

Dmitriy Sonkin, Yue Liu, Raymond Pagliarini, Bill Tschantz, & Michael Morrissey. Identifying SILV as ADC target in melanoma. NVS-DFCI Jt. RETREAT (2010).

Chen, Y. et al. The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma. J. Biol. Chem. 287, 24082–24091 (2012).

Franke, V. et al. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). Int. J. Cancer 145, 974–978 (2019).

Hofland, J., Brabander, T., Verburg, F. A., Feelders, R. A. & De Herder, W. W. Peptide Receptor Radionuclide Therapy. J. Clin. Endocrinol. Metab. 107, 3199–3208 (2022).

Sartor, O. et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 385, 1091–1103 (2021).

Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).

Medina, J. E. et al. Cell-free DNA approaches for cancer early detection and interception. J. Immunother. Cancer 11, e006013 (2023).

Vozenin, M.-C., Bourhis, J. & Durante, M. Towards clinical translation of FLASH radiotherapy. Nat. Rev. Clin. Oncol. 19, 791–803 (2022).

Békés, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181–200 (2022).

Mayor-Ruiz, C. et al. Rational discovery of molecular glue degraders via scalable chemical profiling. Nat. Chem. Biol. 16, 1199–1207 (2020). 32. Munir, T. et al. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. N. Engl. J. Med. NEJMoa2310063 (2023) doi:10.1056/NEJMoa2310063.

Harjunpää, H. & Guillerey, C. TIGIT as an emerging immune checkpoint. Clin. Exp. Immunol. 200, 108–119 (2020).

Rudin, C. M. et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J. Hematol. Oncol.J Hematol Oncol 16, 66 (2023).

Zhou, S., Liu, M., Ren, F., Meng, X. & Yu, J. The landscape of bispecific T cell engager in cancer treatment. Biomark. Res. 9, 38 (2021). 36. Frampton, J. E. Teserpaturev/G47: First Approval. BioDrugs 36, 667–672 (2022).

Tian, Y., Xie, D. & Yang, L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct. Target. Ther. 7, 117 (2022).

Malfitano, A. M., Di Somma, S., Iannuzzi, C. A., Pentimalli, F. & Portella, G. Virotherapy: From single agents to combinatorial treatments. Biochem. Pharmacol. 177, 113986 (2020).

Hawkins, E. R., D’Souza, R. R. & Klampatsa, A. Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy. Biol. Targets Ther. 15, 95–105 (2021).

Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507–516 (2023).

Wellhausen, N. et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci. Transl. Med. 15, eadi1145 (2023).

Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911–926 (2022).

Maia, A. et al. 641 Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab: interim report of the EOGBM1–18/ROSALIE study. in Regular and Young Investigator Award Abstracts A671–A671 (BMJ Publishing Group Ltd, 2022). doi:10.1136/jitc-2022- SITC2022.0641.

Rupaimoole, R. & Slack, F. J. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16, 203–222 (2017).

Padda, I. S., Mahtani, A. U. & Parmar, M. Small Interfering RNA (siRNA) Therapy. in StatPearls (StatPearls Publishing, 2023).

Cuciniello, R., Filosa, S. & Crispi, S. Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics. J. Exp. Clin. Cancer Res. 40, 383 (2021).

Garland, D. E., Moses, B. & Salyer, W. Long-term follow-up of fracture nonunions treated with PEMFs. Contemp. Orthop. 22, 295–302 (1991).

Vadalà, M. et al. Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology. Cancer Med. 5, 3128–3139 (2016).

Vincent, R. L. et al. Probiotic-guided CAR-T cells for solid tumor targeting. Science 382, 211–218 (2023)

Baraldi, J. H., Martyn, G. V., Shurin, G. V. & Shurin, M. R. Tumor Innervation: History, Methodologies, and Significance. Cancers 14, 1979 (2022).

Venkatesh, H. S. Targeting electrochemical communication between neurons and cancer. Sci. Transl. Med. 15, eadi5170 (2023).

Tan, I.-L. et al. Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis. Cell Rep. 42, 113339 (2023).

Yang, H. et al. KLIPP - a precision CRISPR approach to target structural variant junctions in cancer. http://biorxiv.org/lookup/doi/10.1101/2023.05.10.540176 (2023) doi:10.1101/2023.05.10.540176.